Compare SiTime Corporation (SITM) vs Vertex Pharmaceuticals Incorporated (VRTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
SiTime Corporation vs Vertex Pharmaceuticals Incorporated — how do they compare? SiTime Corporation trades at $598 (market cap $16.63B), while Vertex Pharmaceuticals Incorporated trades at $478.06 (market cap $121.95B). The key difference: Vertex Pharmaceuticals Incorporated is far larger — about 7.3× SiTime Corporation's market cap, and Vertex Pharmaceuticals Incorporated is trading nearer its 52-week high, SiTime Corporation nearer its low. Which is the better fit depends on your goals.
| SITM | VRTX | |
|---|---|---|
Market Cap | $16.63B | $121.95B |
Sector | Technology | Health |
52-Week High | $901.60 | $529.59 |
52-Week Low | $190.16 | $366.54 |
Enterprise Value | $15.84B | $116.69B |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About SiTime Corporation
SiTime Corporation is a leading provider of MEMS-based silicon timing solutions used in various electronic applications. The company’s products, including oscillators, resonators, and clock ICs, are designed to replace traditional quartz-based timing devices, offering superior performance, reliability, and smaller size in harsh environments. SiTime's solutions are adopted across high-growth markets such as 5G, data centers, industrial IoT, and automotive, positioning the company as a key enabler for next-generation electronic systems.
Read more on SITM →About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →
